For U.S. Healthcare Professionals Only
Register for Samples

Available in 2 SoloStar® pen options1

The highest capacity basal insulin pen on the market1-5 with double the maximum injection dose of SoloStar in a single injection

The SoloStar pen that your patients know (see study result below)

The pens also share key features:

  • Same pen size
  • 5-second hold time6,7
  • Lowest injection volume of any basal insulin1-5§
  • Known SoloStar platform

*A patient’s dose, if previously an odd number, will need to be adjusted up or down 1 Unit by a healthcare provider if switching from a different pen.

Toujeo Max SoloStar is recommended for appropriate adult patients who require at least 20 Units of basal insulin per day.

Once opened, store at room temperature (below 86°F).

§On a unit-for-unit basis.


The highest capacity basal insulin pen on the market1-5:

The larger capacity pen (900 Units) means:

  • Fewer pens to store
  • Fewer injections for patients requiring greater than 80 Units per dose

Depending on prescription insurance coverage, using fewer pens per year may allow for fewer refills and associated co-pays.


The Toujeo SoloStar pen device:

Key attributes of the Toujeo SoloStar pen:

  • 95% of new start basal insulin patients rated Toujeo SoloStar as easy to use after training and 4 weeks of use, in a study8
    • It is important to train patients on proper product administration
  • Less injection force

Study Design: Pen- and insulin-naive T2DM patients inadequately controlled on OADs were enrolled in a 4-week, multicenter, open-label, single-arm, phase 3b study to evaluate the ease of use/ease of learning of the Toujeo SoloStar pen. On Day 1, patients were trained on use of the device. Only patients who completed the training and demonstrated a successful injection without assistance were eligible for this study (n=40). Toujeo was injected once-daily in the evening. Patients were titrated to a target SMPG of 80-100 mg/dL. Study limitations: potential bias could have been introduced due to the small population and the study's short duration; however, the study was designed to minimize such bias.8

Compared with Lantus® SoloSTAR, FlexPen®, and KwikPen® in a laboratory environment; doses were not delivered into tissue.


How to add Toujeo Max SoloStar and Toujeo SoloStar to your Electronic Medical Record

  • NDC: 0024-5871-02
  • 300 Units/mL formulation
  • 3 mL and 900 Units per pen
  • 2 pens (6 mL and 1800 Units total) per box

Determine how many boxes of Toujeo Max SoloStar a patient will need for a 30-day supply

1 box provides…

Up to 60 Units/day

(total supply dispensed: 6 mL)

2 boxes provide…

61-120 Units/day

(total supply dispensed: 12 mL)

3 boxes provide…

121-180 Units/day

(total supply dispensed: 18 mL)

Unopened pens should be stored in a refrigerator (between 36°F and 46°F) until the expiration date; when opened, store at room temperature (below 86°F)

  • NDC: 0024-5869-03
  • 300 Units/mL formulation
  • 1.5 mL and 450 Units per pen
  • 3 pens (4.5 mL and 1350 Units total) per box

Determine how many boxes of Toujeo SoloStar a patient will need for a 30-day supply

1 box provides…

Up to 45 Units/day

(total supply dispensed: 4.5 mL)

2 boxes provide…

46-90 Units/day

(total supply dispensed: 9 mL)

3 boxes provide…

91-135 Units/day

(total supply dispensed: 13.5 mL)

Unopened pens should be stored in a refrigerator (between 36°F and 46°F) until the expiration date; when opened, store at room temperature (below 86°F)

Clinical profile

Explore the pharmacology, efficacy and safety of Toujeo vs Lantus®

Coverage and savings

Details of coverage and how your eligible patients can save with Toujeo. See comparison example

Toujeo is a long-acting human insulin analog indicated to improve glycemic control in adults with diabetes mellitus.

Limitations of Use: Toujeo is not recommended for treating diabetic ketoacidosis.

Important Safety Information for Toujeo® (insulin glargine injection) 300 Units/mL

Contraindications

Toujeo is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or any of its excipients.

Warnings and Precautions

Toujeo contains the same active ingredient, insulin glargine, as Lantus®. The concentration of insulin glargine in Toujeo is 300 units per mL.

Insulin pens and needles must never be shared between patients. Do NOT reuse needles.

Monitor blood glucose in all patients treated with insulin. Modify insulin regimens cautiously and only under medical supervision. Changes in insulin strength, manufacturer, type, or method of administration may result in the need for a change in insulin dose or an adjustment in concomitant oral antidiabetic treatment. Changes in insulin regimen may result in hyperglycemia or hypoglycemia.

Unit for unit, patients started on, or changed to, Toujeo required a higher dose than patients controlled with Lantus. When changing from another basal insulin to Toujeo, patients experienced higher average fasting plasma glucose levels in the first few weeks of therapy until titrated to their individualized fasting plasma glucose targets. Higher doses were required in titrate-to-target studies to achieve glucose control similar to Lantus®.

Hypoglycemia is the most common adverse reaction of insulin therapy, including Toujeo, and may be life-threatening.

Medication errors, such as accidental mix-ups between basal insulin products and other insulins, particularly rapid-acting insulins, have been reported. Patients should be instructed to always verify the insulin label before each injection.

Do not dilute or mix Toujeo with any other insulin or solution. If mixed or diluted, the solution may become cloudy, and the onset of action/time to peak effect may be altered in an unpredictable manner. Do not administer Toujeo via an insulin pump or intravenously because severe hypoglycemia can occur.

Severe life-threatening, generalized allergy, including anaphylaxis, can occur. Discontinue Toujeo, monitor and treat if indicated.

A reduction in the Toujeo dose may be required in patients with renal or hepatic impairment.

As with all insulins, Toujeo use can lead to life-threatening hypokalemia. Untreated hypokalemia may cause respiratory paralysis, ventricular arrhythmia, and death. Closely monitor potassium levels in patients at risk of hypokalemia and treat if indicated.

Fluid retention, which may lead to or exacerbate heart failure, can occur with concomitant use of thiazolidinediones (TZDs) with insulin. These patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of TZD must be considered.

Drug Interactions

Certain drugs may affect glucose metabolism, requiring insulin dose adjustment and close monitoring of blood glucose. The signs of hypoglycemia may be reduced in patients taking anti-adrenergic drugs (eg, beta-blockers, clonidine, guanethidine, and reserpine).

Adverse Reactions

Adverse reactions commonly associated with Toujeo include hypoglycemia, allergic reactions, injection site reactions, lipodystrophy, pruritus, rash, edema and weight gain.

Important Safety Information for Toujeo® (insulin glargine injection) 300 Units/mL SoloStar® and Toujeo Max SoloStar

Toujeo SoloStar and Toujeo Max SoloStar are disposable prefilled insulin pens. To help ensure an accurate dose each time, patients should follow all steps in the Instruction Leaflet accompanying the pen; otherwise they may not get the correct amount of insulin, which may affect their blood glucose levels. It is especially important to perform a safety test when a patient is using a new pen for the first time.

Do not withdraw Toujeo from the SoloStar and Max SoloStar disposable prefilled pens with a syringe.

All registered trademarks cited are property of their respective owners.

*

*This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, or TRICARE, or similar federal or state programs, including any state pharmaceutical programs. Please note: the Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of this savings program. Void where prohibited by law. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke, or amend the program without notice.

  • First 3 fills for $0, next 12 consecutive fills for $10
  • Maximum savings up to $600 per box, up to 3 boxes
*Eligibility Restrictions This offer is not valid for prescriptions covered by or submitted for reimbursement under Medicare, Medicaid, VA, DOD, TRICARE, or similar federal or state programs including any state pharmaceutical programs. Please note: the Federal Employees Health Benefits (FEHB) Program is not a federal or state government health care program for purposes of this savings program. Void where prohibited by law. Upon registration, patients receive all program details. Sanofi US reserves the right to change the maximum cap amount, rescind, revoke, or amend the program without notice.
Offer Terms for Toujeo Co-Pay Savings Card If your patient is enrolled in a commercial/private insurance plan they will pay a $0 co-pay for the first 3 fills and then pay $10 co-pay for the next 12 consecutive fills for the duration of the program. The Savings Card carries maximum savings of $600 per box. This offer is valid for up to 3 boxes per prescription.
Offer Terms for Insulins Valyou Savings Program: For the duration of the program, eligible patients will pay $149 for each pack of pens. Maximum quantity of ten packs of pens per fill. Offer is valid for one fill per month. When using the Insulins Valyou Savings Card, prices are guaranteed for 12 consecutive monthly fills. This offer is not valid for the Max SoloStar pen. The Insulins Valyou Savings Program applies to the cost of medication. There are other relevant costs associated with overall treatment.

References: 1. Toujeo Prescribing Information. 2. Basaglar Prescribing Information. 3. Lantus Prescribing Information. 4. Levemir Prescribing Information. 5. Tresiba Prescribing Information. 6. Toujeo SoloStar Instructions for Use. 7. Toujeo Max SoloStar Instructions for Use. 8. Pohlmeier H, Berard L, Brulle-Wohlhueter C, et al. J Diabetes Sci Technol. 2016;11(2):263-269. 9. Klonoff D, Nayberg I, Erbstein F, Cali A, Brulle-Wohlhueter C, Haak T. J Diabetes Sci Technol. 2015;9(4):936-938.

© 2019 sanofi-aventis U.S. LLC. All rights reserved.

Legal Disclaimer | Privacy Policy | Contact SANOFI

This site is intended for use by U.S. Healthcare Professionals only.

SAUS.TJO.19.01.0569b Last Update: February 2019

Important Safety Information for Toujeo® (insulin glargine injection) 300 Units/mL

Important Safety Information

Contraindications

Toujeo is contraindicated during episodes of hypoglycemia and in patients hypersensitive to insulin glargine or any of its excipients.

Warnings and Precautions

Toujeo contains the same active ingredient, insulin glargine, as Lantus®. The concentration of insulin glargine in Toujeo is 300 units per mL.

Insulin pens and needles must never be shared between patients. Do NOT reuse needles.

Monitor blood glucose in all patients treated with insulin. Modify insulin regimens cautiously and only under medical supervision. Changes in insulin